Inovio Pharmaceuticals Number Of Shares Shorted vs. EBITDA
| INO Stock | USD 3.98 0.05 1.24% |
For Inovio Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Inovio Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Inovio Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Inovio Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Inovio Pharmaceuticals over time as well as its relative position and ranking within its peers.
Inovio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Inovio Pharmaceuticals EBITDA vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Inovio Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Inovio Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Inovio Pharmaceuticals is rated fourth overall in number of shares shorted category among its peers. It is rated below average in ebitda category among its peers . Inovio Pharmaceuticals reported last year EBITDA of (130.39 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inovio Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Inovio EBITDA vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Inovio Pharmaceuticals |
| = | 3.75 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Inovio Pharmaceuticals |
| = | (130.39 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Inovio EBITDA Comparison
Inovio Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Inovio Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Inovio Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Inovio Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Inovio Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Inovio Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -662.6 K | -629.5 K | |
| Operating Income | -135.2 M | -128.5 M | |
| Income Before Tax | -135.1 M | -128.4 M | |
| Total Other Income Expense Net | 109.3 K | 114.8 K | |
| Net Loss | -135.1 M | -128.4 M | |
| Income Tax Expense | 2.00 | 1.90 | |
| Net Loss | -164.6 M | -172.8 M | |
| Non Operating Income Net Other | -1.1 M | -1.2 M | |
| Net Loss | -251.8 M | -239.2 M | |
| Interest Income | 8.2 M | 8.6 M | |
| Net Interest Income | 6.9 M | 7.3 M | |
| Change To Netincome | 34.5 M | 20.1 M | |
| Net Loss | (6.09) | (6.40) | |
| Income Quality | 0.92 | 0.87 | |
| Net Income Per E B T | 1.19 | 1.13 |
Inovio Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Inovio Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Inovio Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Inovio Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Inovio Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Use Investing Themes to Complement your Inovio Pharmaceuticals position
In addition to having Inovio Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Moderate Funds Thematic Idea Now
Moderate Funds
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
To fully project Inovio Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Inovio Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Inovio Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.